Evidence map›Paper›PMID 27229901›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2016

Nanoparticles and direct immunosuppression.

Terrika A Ngobili, Michael A Daniele

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints.International journal of molecular sciences · 2022
    Review
  16. Review
  17. Article
  18. Biocompatibility of nanomaterials and their immunological properties.Biomedical materials (Bristol, England) · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Terrika A NgobiliJoint Department of Biomedical Engineering, North Carolina State University and University of North Carolina, Chapel Hill, Raleigh, NC 27695, USA.
Michael A DanieleJoint Department of Biomedical Engineering, North Carolina State University and University of North Carolina, Chapel Hill, Raleigh, NC 27695, USA Department of Electrical & Computer Engineering, North Carolina State University, Raleigh, NC 27695, USA mdaniel6@ncsu.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting the immune system with nanomaterials is an intensely active area of research. Specifically, the capability to induce immunosuppression is a promising complement for drug delivery and regenerative medicine therapies. Many novel strategies for immunosuppression rely on nanoparticles as delivery vehicles for small-molecule immunosuppressive compounds. As a consequence, efforts in understanding the mechanisms in which nanoparticles directly interact with the immune system have been overshadowed. The immunological activity of nanoparticles is dependent on the physiochemical properties of the nanoparticles and its subsequent cellular internalization. As the underlying factors for these reactions are elucidated, more nanoparticles may be engineered and evaluated for inducing immunosuppression and complementing immunosuppressive drugs. This review will briefly summarize the state-of-the-art and developments in understanding how nanoparticles induce immunosuppressive responses, compare the inherent properties of nanomaterials which induce these immunological reactions, and comment on the potential for using nanomaterials to modulate and control the immune system.

Indexed as

AnimalsDrug CarriersHumansImmunosuppression TherapyImmunosuppressive AgentsNanoparticlesDrug CarriersImmunosuppressive Agentsanti-inflammatorybionanoscienceimmunosuppressionimmunotoxicityNanoparticlesnanotoxicology

Identifiers

PMID27229901
PMCPMC4950368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.